Associated tags: Cloud, Degenerative disease, Death, Shawn, Silver, ECG, Cardiovascular disease, Artificial intelligence, FDA, Heart, Pharmaceutical industry
Retrieved on:
Tuesday, October 19, 2021
People,
Cloud,
Degenerative disease,
Death,
Shawn,
Silver,
ECG,
Cardiovascular disease,
Artificial intelligence,
FDA,
Heart,
Pharmaceutical industry FRANKFURT, Germany, Oct. 19, 2021 /PRNewswire/ -- Cardisio GmbH, developers of the world's first non-invasive, highly accurate screening method for heart diseases, today announced completion of its largest investment round to date.
Key Points:
- FRANKFURT, Germany, Oct. 19, 2021 /PRNewswire/ -- Cardisio GmbH, developers of the world's first non-invasive, highly accurate screening method for heart diseases, today announced completion of its largest investment round to date.
- A group of private investors has infused 3.5 million in Cardisio.
- Cardisio GmbH is headquartered in Frankfurt, Germany, and has offices in Berlin and San Francisco.
- Cardisio is a registered trademark of Cardisio GmbH.
Circulatory system,
Cardiovascular system,
RTT,
Medicine,
Aging-associated diseases,
Coronary artery disease,
Acute pain,
Coronary arteries,
Cardiology,
Myocardial infarction,
Atheroma,
Variant angina FRANKFURT, Germany, Jan. 13, 2020 /PRNewswire/ --The Journal of Electrocardiology has published a study showing unparalleled accuracy in non-invasive coronary artery disease (CAD) detection using Cardisio's new low-cost method which involves no radiation exposure.
Key Points:
- FRANKFURT, Germany, Jan. 13, 2020 /PRNewswire/ --The Journal of Electrocardiology has published a study showing unparalleled accuracy in non-invasive coronary artery disease (CAD) detection using Cardisio's new low-cost method which involves no radiation exposure.
- People with coronary artery disease are frequently symptom-free until the onset of a severe event such as a heart attack.
- "We see great potential in Cardisiography for early detection of symptom-free people with coronary artery disease.
- Headquartered in Frankfurt, Germany, with offices in Berlin and San Francisco, Cardisio is a privately-held mobile health tech company that develops non-invasive, highly accurate tests for detecting coronary artery disease.
